One of the biggest barriers to bone marrow transplant (BMT) for many patients worldwide has been finding a HLA-matched donor. With smaller families in many countries, the chance of having a full HLA-matched sibling is often only 20–30%. India’s top BMT centres have now made haploidentical BMT — using a half-matched family donor — a routine, established treatment option, opening BMT access to a far larger pool of patients.
A haploidentical (or “haplo”) transplant uses a donor who is a half-match — typically a parent, child or sibling. Until about a decade ago, only fully matched sibling donors were considered safe for allogeneic BMT. Advances in conditioning regimens (particularly post-transplant cyclophosphamide) have made half-matched transplants nearly as effective as fully matched, with manageable risks.
Many patients with leukaemia, lymphoma, multiple myeloma, thalassaemia, sickle cell disease or severe aplastic anaemia cannot find a matched sibling donor. Without haploidentical BMT, the only options are:
Haploidentical BMT solves this by allowing virtually any parent, child or sibling to be a donor — meaning most patients have at least one possible donor in their family.
BLK Max, New Delhi — one of India’s highest-volume haematology and BMT centres with established autologous, allogeneic, haploidentical and MUD transplant programmes.
→ Read full BMT guide for international patients
Get a free medical opinion and cost estimate from India’s top hospitals — within 24 hours.